These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 27220797)

  • 1. [Standard Cancer Therapy Are Established by the Investigator-Initiated Post-Marketing Clinical Trials, Not by the Indication-Directed Clinical Trials].
    Shimada Y
    Gan To Kagaku Ryoho; 2016 Apr; 43(4):473-5. PubMed ID: 27220797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Activity and Future Perspective of Local Independent Clinical Trial Group (OGSG)].
    Tsujinaka T
    Gan To Kagaku Ryoho; 2016 Apr; 43(4):470-2. PubMed ID: 27220796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Response of Pharmaceutical Companies to the Crisis of Post-Marketing Clinical Trials of Anti-Cancer Agents -- Results of Questionnaires to Pharmaceutical Companies].
    Nakajima T
    Gan To Kagaku Ryoho; 2016 Apr; 43(4):486-9. PubMed ID: 27220801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Post launch studies].
    Akaza H; Ohashi Y; Shimada Y; Ikeda T; Saijo N; Isonishi S; Hirao Y; Tsuruo T; Tsukagoshi S; Sone S; Nakamura S; Kato M; Mikami O; von Euler M; Blackledge G; Milsted B; Vose B
    Gan To Kagaku Ryoho; 2002 Nov; 29(11):2037-48. PubMed ID: 12465411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical trials and studies of the German Society for Paediatric Oncology and Haematology (GPOH) and the European Directive for the Implementation of Good Clinical Practice in the Conduct of Clinical Trials].
    Graf N; Göbel U
    Klin Padiatr; 2004; 216(3):129-31. PubMed ID: 15175956
    [No Abstract]   [Full Text] [Related]  

  • 6. Quality evaluation of investigator-initiated trials using post-approval cancer drugs in Japan.
    Kondo S; Hosoi H; Itahashi K; Hashimoto J
    Cancer Sci; 2017 May; 108(5):995-999. PubMed ID: 28266163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.
    Vogelzang NJ; Benowitz SI; Adams S; Aghajanian C; Chang SM; Dreyer ZE; Janne PA; Ko AH; Masters GA; Odenike O; Patel JD; Roth BJ; Samlowski WE; Seidman AD; Tap WD; Temel JS; Von Roenn JH; Kris MG
    J Clin Oncol; 2012 Jan; 30(1):88-109. PubMed ID: 22147736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The revision of Guidelines for Clinical Evaluation Methods of Anti-Cancer Drugs in Japan].
    Andoh M; Fujiwara Y; Shimada Y
    Gan To Kagaku Ryoho; 2006 Jul; 33(7):1015-9. PubMed ID: 16878363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Development of anti-cancer drugs under new renewed GCP--from the viewpoint of drug development company developer].
    Ueno T; Kobayashi T; Inoue K; Yanagi Y; Yamada Y
    Gan To Kagaku Ryoho; 1998 Apr; 25(5):663-70. PubMed ID: 9571963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trend toward noninferiority trials may mean more difficult interpretation of trial results.
    Tuma RS
    J Natl Cancer Inst; 2007 Dec; 99(23):1746-8. PubMed ID: 18042926
    [No Abstract]   [Full Text] [Related]  

  • 11. American Society of Clinical Oncology policy statement: oversight of clinical research.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Compensation guidelines for research-related injury in India could destroy investigator-initiated research.
    Pramesh CS; Badwe RA
    Natl Med J India; 2012; 25(1):35-7. PubMed ID: 22680323
    [No Abstract]   [Full Text] [Related]  

  • 13. [Importance of Post-Marketing Studies in Gathering of Clinical Evidences for Proper Usage of Anti-Cancer Drugs, and the StudyRequirements for Their Credibility].
    Inagaki O
    Gan To Kagaku Ryoho; 2016 Apr; 43(4):480-2. PubMed ID: 27220799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The current status and future perspectives of CSPOR-BC.
    Aihara T; Mukai H
    Breast Cancer; 2013 Oct; 20(4):287-90. PubMed ID: 22739808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Let Us to Know the Post-Marketing Clinical Studies and Critical Situation of Study Groups -- Now We Should Talk about How to Achieve the Safe and Most Effective Treatment for Cancer Patients].
    Hamamoto M
    Gan To Kagaku Ryoho; 2016 Apr; 43(4):490-3. PubMed ID: 27220802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Emetogenic potential of antineoplastic agents based on clinical trials in Japan].
    Watanabe T; Handa S; Kato Y
    Gan To Kagaku Ryoho; 2015 Mar; 42(3):335-41. PubMed ID: 25812503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer clinical trials: development and implementation.
    Vail DM
    Vet Clin North Am Small Anim Pract; 2007 Nov; 37(6):1033-57; v. PubMed ID: 17950881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of cancer cooperative groups in Japan.
    Fukuda H
    Jpn J Clin Oncol; 2010 Sep; 40(9):881-90. PubMed ID: 20670961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Focus on academic multicenter trials: impact of the German drug law on hematological/oncological therapy optimization trials].
    Ihrig K; Fath B; Fuchs M; Hallek M; Marschner N; Naumann R; Röllig C; Saussele S; Tesch H; Gökbuget N
    Onkologie; 2013; 36 Suppl 2():23-8. PubMed ID: 23549033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Current status and issues in clinical trials of anticancer agents].
    Kojima H
    Gan To Kagaku Ryoho; 1994 Oct; 21 Suppl 3():295-301. PubMed ID: 7986107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.